Lipella Pharmaceuticals regains Nasdaq equity compliance after $5.9M placement

LIPELLA PHARMACEUTICALS INC.

Final closing of Series B convertible preferred stock offering on March 12, 2025; net proceeds ~$5.9M.
Also issued warrants to purchase up to 72,000 Series B shares at $100/share on March 17, 2025; gross proceeds $9,000.
Stockholders' equity was ~$1.9M as of Dec 31, 2024; after offerings, company believes it meets Nasdaq's Stockholders' Equity Requirement.
Nasdaq continued listing is subject to compliance; company states it currently remains in compliance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.